Regulators require certain research and testing is done to launch nicotine products, but, for responsible manufacturers, going beyond this routine testing is a must. To that end, Imperial Brands conducts ‘actual use’ behavioural studies featuring real adult smoker participants in actual next generation product (NGP) markets. Here, the seven key learnings of two years’ worth of actual use studies of its blu range of vapes are explored.
Immediate impact of vapes
Vaping is well-established as a means of giving up smoking with even the NHS describing it as “one of the most effective tools for quitting smoking.” However, the speed at which vapes can help users make the switch from combustible cigarettes varies from product-to-product.
Therefore, it is significant that all of the blu actual use studies found that vaping has a near-instant impact on participants’ smoking behaviour, with the majority of smoking reduction occurring in week one of each study.
Sustained reduction in smoking
In November 2025, the BBC broke the news that “for the first time, there are more over-16s using vapes or e-cigarettes than smoking cigarettes.” Commenting on this news at the time, Action on Smoking and Health said, “the evidence that vaping is displacing smoking among adults is good news for public health as vaping is less harmful and shown to be a valuable aid to quitting smoking.”
The evidence is clear, using vapes as an alternative to cigarettes must be sustained, rather than a flash in the pan, to meet harm reduction goals.
Therefore, it is positive that the strong start in smoking reduction observed in the blu studies was sustained throughout the whole six-week period observed and maintained at 24-week follow ups. In other words, vaping helped significant numbers of participants either substantially reduce their smoking, or even leave cigarettes/nicotine behind entirely.
Flavours support switching
The evidence from the studies was clear; flavours helped to drive substantial changes in smoking behaviour in favour of moving away from combustible cigarettes.
This observation is in line with our recently published literature review of 230 peer-reviewed studies, which is available on PubMed. It found that when responsible formulation, realistic testing and context-based risk assessment are applied, flavoured vaping products offer meaningful public health benefits and they can play a major role in tobacco harm reduction (THR) strategies.
Varied vape flavours is key
Supporting participants across each study to transition from smoking to vaping worked best were a range of flavours was available. All participants who stopped smoking entirely at the end of the studies exclusively used fruit and/or menthol flavoured vapes.
Therefore, it is clear that a wide range of responsibly manufactured and marketed flavours are clearly important in helping drive and support positive changes in smoking behaviour.
Gender and age divides in flavours
Another key takeaway concerning vape flavours was the differing preferences observed between male and female participants and across the different age groups studied.
Many male participants heavily favoured fresh mint pods while female participants generally opted for a wider variety of flavours.
When it comes to ages, participants aged 19 to 24 consumed Fresh Mint pods most often, those aged 25 to 44 liked Fresh Mint and Blueberry Ice, and participants aged between 45 and 64 saw an increase in Golden Tobacco use over time. The 45 to 64 age group also reported high usage of other flavours.
These findings continue to make the case that a wide range of quality, responsible flavours are crucial; they encourage trial – and support switching – across a broad range of demographics.
Increased motivation to quit smoking
Encouragingly, participants expressed increasingly positive feelings as they vaped during the studies, including satisfaction, enjoyment, ease of use and relief from smoking cravings. These responses coincided with increasing motivation to stop smoking as the studies progressed.
For example, 5.4 per cent of smokers in the blu 2.0 study initially reported a strong desire in intention to stop smoking in the short to medium term. This more than doubled to 11.3 per cent at week-two and had quadrupled to 21.3 per cent by week-6. From there, it remained generally stable until follow-up at week–24.
THR should be taken seriously
Contrary to the stance of some public health bodies and regulators, our actual use studies provide more compelling evidence that NGP like vapes can potentially contribute to better public health outcomes. For example, across both blu studies, participants smoked approximately 140,000 fewer cigarettes in only six weeks.
This is in line with the position of respected academics operating in the sector. For example, Derek Yach, the first director of the World Health Organisation’s Tobacco Free Initiative, last article published on The Lancet explained why WHO should embrace THR to save lives by helping adult smokers switch to safer alternatives like vapes.
Imperial Brands will publish the full results of both blu actual-use studies in peer-reviewed academic literature later this year. Subscribe to its blog to stay up-to-date as we continue to share the latest scientific evidence on vaping and THR.